Gilteritinib

In this article, we will discuss Gilteritinib (Dosage Overview). So, let’s get started.

Indications

Relapsed or Refractory Acute Myeloid Leukemia

Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.

Dosage

Patient Selection
Select patients for the treatment of AML with Gilteritinib based on the presence of FLT3 mutations in the blood or bone marrow.

Recommended Dosage

The recommended starting dose of XOSPATA is 120 mg orally once daily with or without food. Response may be delayed. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.

Do not break or crush Gilteritinib tablets. Administer Gilteritinib tablets orally about the same time each day. If a dose of Gilteritinib is missed or not taken at the usual time, administer the dose as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.

One thought on “Gilteritinib

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.